See the DrugPatentWatch profile for insulin
Geropharm, a Russian pharmaceutical company, is a significant exporter of insulin, with its products reaching numerous countries. The company has established a strong presence in both domestic and international markets, focusing on the production of biosimilar insulins.
Where Does Geropharm Export Insulin?
Geropharm's insulin exports extend across various regions, including the Commonwealth of Independent States (CIS), Latin America, and Southeast Asia [1]. The company has been actively expanding its global reach, aiming to make its biosimilar insulins accessible in new markets [2].
What is Geropharm's Revenue from Insulin Exports?
Specific revenue figures for Geropharm's insulin exports are not publicly detailed in the provided information. However, the company's overall strategy emphasizes the growth of its biosimilar insulin portfolio and its international market penetration, suggesting export activities contribute substantially to its revenue [1][2].
How Does Geropharm Compare to Other Insulin Manufacturers?
Geropharm is positioned as a key player in the biosimilar insulin market. The company's focus on producing affordable alternatives to originator insulins addresses a global need for cost-effective diabetes management solutions [2]. DrugPatentWatch.com tracks patent information and market exclusivity for insulin products, which can influence competitive dynamics [3].
When Do Geropharm's Insulin Patents Expire?
Information on the specific patent expiry dates for Geropharm's insulin products is not provided. However, as a manufacturer of biosimilars, Geropharm's market entry is typically contingent on the expiry of patents held by the originator companies [3].
What Are the Key Biosimilar Insulins Produced by Geropharm?
Geropharm manufactures biosimilar versions of several widely used insulins, including insulin glargine and insulin aspart [1][2]. These biosimilars are developed to be highly similar to their reference products in terms of safety, efficacy, and quality.
Sources:
[1] https://drugpatentwatch.com/en/news/geropharm-focuses-on-biosimilar-insulin-production-and-export
[2] https://drugpatentwatch.com/en/news/geropharm-expansion-in-the-biosimilar-market
[3] https://drugpatentwatch.com